Germany requests 5% of EU supply of remdesivir

FILE PHOTO: An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020. Ulrich Perrey/Pool via REUTERS/File Photo

BERLIN (Reuters) - Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19.

Berlin has requested 155,000 vials of remdesivir under the EU's six-month deal to buy up to 3 million vials from U.S. drug maker Gilead, the ministry said in a statement.